Drug
Edp 323
Edp 323: highest development phase Phase 1, developed by Enanta Pharmaceuticals. 3 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Enanta Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| EDP-323 NCT06917508 | Phase 1 | RSV Infection |
| EDP-323 NCT06847464 | Phase 1 | RSV Infection |
| EDP-323 NCT05587478 | Phase 1 | RSV Infection |
Latest
No recent events.
Follow Edp 323 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.